2 active not recruiting, 1 completed, 1 unknown. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow bictegravir: new trials by email Literature Review of bictegravir trials Research Report on bictegravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC, Bictegravir/Lenacapavir - HIV-1-infection | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 75 | 2024-11-20 | 2026-09-29 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) Bictegravir, Lenacapavir, BIC/LEN FDC - HIV-1-infection | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 689 | 2022-08-16 | 2026-10-21 |
| Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide - HIV Primary Infection | Phase 2 | Unknown | Anna Cruceta | 66 | 2020-12-04 | 2021-07-19 |
| Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults BIC, F/TAF, DTG - HIV-1 Infection | Phase 2 | Completed | Gilead Sciences | 98 | 2015-03-23 | 2020-04-07 |
Acquired Immunodeficiency Syndrome (1)
Gilead Sciences (3) · Anna Cruceta (1)
Spain (3) · United States (3) · Argentina (2) · Italy (2) · South Africa (2) · Australia (1) · Canada (1) · Dominican Republic (1) · France (1) · Germany (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
PMID 28219610, PMID 29794828, PMID 41313173, PMID 41763229
2023 (1)